ChemoCentryx, Inc. (CCXI) Rating Increased to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a hold rating to a buy rating in a research report report published on Tuesday morning. The firm currently has $9.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
A number of other analysts have also recently commented on the stock. BidaskClub cut shares of ChemoCentryx from a buy rating to a hold rating in a research note on Friday, August 18th. Cowen and Company reiterated a hold rating on shares of ChemoCentryx in a research note on Tuesday, August 8th.
ChemoCentryx (CCXI) opened at 7.89 on Tuesday. The company’s market cap is $384.29 million. The company’s 50-day moving average is $7.43 and its 200-day moving average is $7.82. ChemoCentryx has a 12 month low of $5.19 and a 12 month high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The firm had revenue of $8.94 million for the quarter. On average, equities research analysts expect that ChemoCentryx will post ($0.90) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/14/chemocentryx-inc-ccxi-rating-increased-to-buy-at-zacks-investment-research.html.
Hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in ChemoCentryx in the 2nd quarter worth approximately $102,000. JPMorgan Chase & Co. acquired a new stake in ChemoCentryx in the 2nd quarter worth approximately $104,000. Voya Investment Management LLC boosted its stake in ChemoCentryx by 22.8% in the 2nd quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 2,965 shares in the last quarter. Trexquant Investment LP boosted its stake in ChemoCentryx by 81.1% in the 2nd quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 8,327 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in ChemoCentryx in the 2nd quarter worth approximately $178,000. Institutional investors own 50.12% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.